the underlying diseases in the 64 patients included in the evaluation of efficacy were acute myelocytic leukemia ( 30 cases ) , acute lymphocytic leukemia ( 9 ) , acute promyelocytic leukemia ( 3 ) , acute monocytic leukemia ( 2 ) , chronic myelocytic leukemia-blastic crisis ( 10 ) , erythroleukemia ( 2 ) , malignant lymphoma ( 2 ) , aplastic anemia ( 2 ) , and others ( 4 ) .
C0023467
acute
C0023487
acute